A 0 1 0 1 O
minimum 2 9 2 9 O
of 10 12 10 12 O
3 13 14 13 14 B-lower_bound
rising 15 21 15 21 O
PSA 22 25 22 25 O
values 26 32 26 32 O
with 33 37 33 37 O
an 38 40 38 40 O
interval 41 49 41 49 O
of 50 52 50 52 O
at 53 55 53 55 O
least 56 61 56 61 O
1 62 63 62 63 B-lower_bound
week 64 68 64 68 I-lower_bound
between 69 76 69 76 O
determinations 77 91 77 91 O

Any 0 3 92 95 O
other 4 9 96 101 O
acute 10 15 102 107 B-chronic_disease
or 16 18 108 110 I-chronic_disease
chronic 19 26 111 118 I-chronic_disease
medical 27 34 119 126 I-chronic_disease
or 35 37 127 129 O
psychiatric 38 49 130 141 B-chronic_disease
condition 50 59 142 151 I-chronic_disease
( 60 61 152 153 O
concurrent 61 71 153 163 O
disease 72 79 164 171 O
, 79 80 171 172 O
infection 81 90 173 182 B-chronic_disease
, 90 91 182 183 O
or 92 94 184 186 O
comorbidity 95 106 187 198 O
) 106 107 198 199 O
that 108 112 200 204 O
interferes 113 123 205 215 O
with 124 128 216 220 O
ability 129 136 221 228 O
to 137 139 229 231 O
participate 140 151 232 243 O
in 152 154 244 246 O
the 155 158 247 250 O
study 159 164 251 256 O
, 164 165 256 257 O
causes 166 172 258 264 O
undue 173 178 265 270 O
risk 179 183 271 275 O
, 183 184 275 276 O
or 185 187 277 279 O
complicates 188 199 280 291 O
the 200 203 292 295 O
interpretation 204 218 296 310 O
of 219 221 311 313 O
data 222 226 314 318 O
, 226 227 318 319 O
in 228 230 320 322 O
the 231 234 323 326 O
opinion 235 242 327 334 O
of 243 245 335 337 O
the 246 249 338 341 O
investigator 250 262 342 354 O
or 263 265 355 357 O
sponsor 266 273 358 365 O
, 273 274 365 366 O
including 275 284 367 376 O
recent 285 291 377 383 O
( 292 293 384 385 O
within 293 299 385 391 O
the 300 303 392 395 O
past 304 308 396 400 O
year 309 313 401 405 O
) 313 314 405 406 O
or 315 317 407 409 O
active 318 324 410 416 O
suicidal 325 333 417 425 B-chronic_disease
ideation 334 342 426 434 I-chronic_disease
or 343 345 435 437 O
behavior 346 354 438 446 O
or 355 357 447 449 O
laboratory 358 368 450 460 O
abnormality 369 380 461 472 O
that 381 385 473 477 O
may 386 389 478 481 O
increase 390 398 482 490 O
the 399 402 491 494 O
risk 403 407 495 499 O
associated 408 418 500 510 O
with 419 423 511 515 O
study 424 429 516 521 O
participation 430 443 522 535 O
or 444 446 536 538 O
investigational 447 462 539 554 O
product 463 470 555 562 O
administration 471 485 563 577 O
or 486 488 578 580 O
may 489 492 581 584 O
interfere 493 502 585 594 O
with 503 507 595 599 O
the 508 511 600 603 O
interpretation 512 526 604 618 O
of 527 529 619 621 O
study 530 535 622 627 O
results 536 543 628 635 O
and 544 547 636 639 O
, 547 548 639 640 O
in 549 551 641 643 O
the 552 555 644 647 O
judgment 556 564 648 656 O
of 565 567 657 659 O
the 568 571 660 663 O
investigator 572 584 664 676 O
, 584 585 676 677 O
would 586 591 678 683 O
make 592 596 684 688 O
the 597 600 689 692 O
patient 601 608 693 700 O
inappropriate 609 622 701 714 O
for 623 626 715 718 O
entry 627 632 719 724 O
into 633 637 725 729 O
this 638 642 730 734 O
study 643 648 735 740 O

At 0 2 741 743 O
least 3 8 744 749 O
18 9 11 750 752 B-lower_bound
years 12 17 753 758 I-lower_bound
of 18 20 759 761 O
age 21 24 762 765 B-age

Bilateral 0 9 766 775 B-treatment
orchiectomy 10 21 776 787 I-treatment
or 22 24 788 790 O
ongoing 25 32 791 798 O
androgen 33 41 799 807 B-treatment
deprivation 42 53 808 819 I-treatment
therapy 54 61 820 827 I-treatment
with 62 66 828 832 I-treatment
a 67 68 833 834 I-treatment
gonadotropin 69 81 835 847 I-treatment
- 81 82 847 848 I-treatment
releasing 82 91 848 857 I-treatment
hormone 92 99 858 865 I-treatment
( 100 101 866 867 I-treatment
GnRH 101 105 867 871 I-treatment
) 105 106 871 872 I-treatment
agonist 107 114 873 880 I-treatment
/ 114 115 880 881 I-treatment
antagonist 115 125 881 891 I-treatment
( 126 127 892 893 O
surgical 127 135 893 901 B-treatment
or 136 138 902 904 I-treatment
medical 139 146 905 912 I-treatment
castration 147 157 913 923 I-treatment
) 157 158 923 924 O

Bisphosphonate 0 14 925 939 B-treatment
or 15 17 940 942 O
denosumab 18 27 943 952 B-treatment
dosage 28 34 953 959 O
must 35 39 960 964 O
have 40 44 965 969 O
been 45 49 970 974 O
stable 50 56 975 981 O
for 57 60 982 985 O
at 61 63 986 988 O
least 64 69 989 994 O
4 70 71 995 996 B-lower_bound
weeks 72 77 997 1002 I-lower_bound
before 78 84 1003 1009 O
day 85 88 1010 1013 O
1 89 90 1014 1015 O
for 91 94 1016 1019 O
patients 95 103 1020 1028 O
receiving 104 113 1029 1038 O
these 114 119 1039 1044 O
therapies 120 129 1045 1054 B-treatment

Bone 0 4 1055 1059 B-chronic_disease
disease 5 12 1060 1067 I-chronic_disease
progression 13 24 1068 1079 O
defined 25 32 1080 1087 O
by 33 35 1088 1090 O
PCWG3 36 41 1091 1096 O
with 42 46 1097 1101 O
2 47 48 1102 1103 B-lower_bound
or 49 51 1104 1106 O
more 52 56 1107 1111 O
new 57 60 1112 1115 O
metastatic 61 71 1116 1126 B-cancer
lesions 72 79 1127 1134 I-cancer
on 80 82 1135 1137 O
bone 83 87 1138 1142 O
scan 88 92 1143 1147 O

Clinically 0 10 1148 1158 O
significant 11 22 1159 1170 O
cardiovascular 23 37 1171 1185 B-chronic_disease
disease 38 45 1186 1193 I-chronic_disease

Current 0 7 1194 1201 O
or 8 10 1202 1204 O
anticipated 11 22 1205 1216 O
use 23 26 1217 1220 O
within 27 33 1221 1227 O
7 34 35 1228 1229 B-upper_bound
days 36 40 1230 1234 I-upper_bound
prior 41 46 1235 1240 I-upper_bound
to 47 49 1241 1243 O
first 50 55 1244 1249 O
dose 56 60 1250 1254 O
of 61 63 1255 1257 O
study 64 69 1258 1263 O
drug 70 74 1264 1268 O
or 75 77 1269 1271 O
anticipated 78 89 1272 1283 O
use 90 93 1284 1287 O
during 94 100 1288 1294 O
the 101 104 1295 1298 O
study 105 110 1299 1304 O
of 111 113 1305 1307 O
the 114 117 1308 1311 O
following 118 127 1312 1321 O
P 128 129 1322 1323 O
gp 130 132 1324 1326 O
inhibitors 133 143 1327 1337 O
( 144 145 1338 1339 O
amiodarone 145 155 1339 1349 B-treatment
, 155 156 1349 1350 O
carvedilol 157 167 1351 1361 B-treatment
, 167 168 1361 1362 O
clarithromycin 169 183 1363 1377 B-treatment
, 183 184 1377 1378 O
cobicistat 185 195 1379 1389 B-treatment
, 195 196 1389 1390 O
darunavir 197 206 1391 1400 B-treatment
, 206 207 1400 1401 O
dronedarone 208 219 1402 1413 B-treatment
, 219 220 1413 1414 O
erythromycin 221 233 1415 1427 B-treatment
, 233 234 1427 1428 O
indinavir 235 244 1429 1438 B-treatment
, 244 245 1438 1439 O
itraconazole 246 258 1440 1452 B-treatment
, 258 259 1452 1453 O
ketoconazole 260 272 1454 1466 B-treatment
, 272 273 1466 1467 O
lapatinib 274 283 1468 1477 B-treatment
, 283 284 1477 1478 O
lopinavir 285 294 1479 1488 B-treatment
, 294 295 1488 1489 O
propafenone 296 307 1490 1501 B-treatment
, 307 308 1501 1502 O
quinidine 309 318 1503 1512 B-treatment
, 318 319 1512 1513 O
ranolazine 320 330 1514 1524 B-treatment
, 330 331 1524 1525 O
ritonavir 332 341 1526 1535 B-treatment
, 341 342 1535 1536 O
saquinavir 343 353 1537 1547 B-treatment
, 353 354 1547 1548 O
telaprevir 355 365 1549 1559 B-treatment
, 365 366 1559 1560 O
tipranavir 367 377 1561 1571 B-treatment
, 377 378 1571 1572 O
verapamil 379 388 1573 1582 B-treatment
, 388 389 1582 1583 O
and 390 393 1584 1587 O
valspodar 394 403 1588 1597 B-treatment
) 403 404 1597 1598 O

DNA 0 3 1599 1602 B-chronic_disease
damage 4 10 1603 1609 I-chronic_disease
repair 11 17 1610 1616 I-chronic_disease
deficiency 18 28 1617 1627 I-chronic_disease
as 29 31 1628 1630 O
assessed 32 40 1631 1639 O
centrally 41 50 1640 1649 O
by 51 53 1650 1652 O
a 54 55 1653 1654 O
gene 56 60 1655 1659 O
mutation 61 69 1660 1668 O
biomarker 70 79 1669 1678 O
panel 80 85 1679 1684 O
( 86 87 1685 1686 O
testing 87 94 1686 1693 O
of 95 97 1694 1696 O
de 98 100 1697 1699 B-cancer
novo 101 105 1700 1704 I-cancer
or 106 108 1705 1707 I-cancer
archival 109 117 1708 1716 I-cancer
tumor 118 123 1717 1722 I-cancer
tissue 124 130 1723 1729 I-cancer
( 131 132 1730 1731 O
via 132 135 1731 1734 O
central 136 143 1735 1742 O
laboratory 144 154 1743 1753 O
) 154 155 1753 1754 O
or 156 158 1755 1757 O
prior 159 164 1758 1763 O
historical 165 175 1764 1774 O
testing 176 183 1775 1782 O
( 184 185 1783 1784 O
with 185 189 1784 1788 O
Sponsor 190 197 1789 1796 O
approval 198 206 1797 1805 O
) 206 207 1805 1806 O
using 208 213 1807 1812 O
the 214 217 1813 1816 O
Foundation 218 228 1817 1827 O
Medicine 229 237 1828 1836 O
, 237 238 1836 1837 O
FoundationOne 239 252 1838 1851 O
CDx 253 256 1852 1855 O
â„¢ 256 257 1855 1856 O
NGS 258 261 1857 1860 O
gene 262 266 1861 1865 O
panel 267 272 1866 1871 O
test 273 277 1872 1876 O

Documented 0 10 1877 1887 O
disease 11 18 1888 1895 O
progression 19 30 1896 1907 O
( 31 32 1908 1909 O
either 32 38 1909 1915 O
radiographic 39 51 1916 1928 B-treatment
or 52 54 1929 1931 O
biochemical 55 66 1932 1943 B-treatment
) 66 67 1943 1944 O
on 68 70 1945 1947 O
at 71 73 1948 1950 O
least 74 79 1951 1956 O
1 80 81 1957 1958 B-lower_bound
novel 82 87 1959 1964 B-treatment
hormonal 88 96 1965 1973 I-treatment
therapy 97 104 1974 1981 I-treatment
( 105 106 1982 1983 O
enzalutamide 106 118 1983 1995 B-treatment
and/or 119 125 1996 2002 O
abiraterone 126 137 2003 2014 B-treatment
acetate 138 145 2015 2022 I-treatment
/ 145 146 2022 2023 O
prednisone 146 156 2023 2033 B-treatment
) 156 157 2033 2034 O
for 158 161 2035 2038 O
the 162 165 2039 2042 O
treatment 166 175 2043 2052 B-treatment
of 176 178 2053 2055 O
metastatic 179 189 2056 2066 B-cancer
CRPC 190 194 2067 2071 I-cancer
, 194 195 2071 2072 O
irrespective 196 208 2073 2085 O
of 209 211 2086 2088 O
prior 212 217 2089 2094 B-treatment
NHT 218 221 2095 2098 I-treatment
treatment 222 231 2099 2108 I-treatment
for 232 235 2109 2112 O
non 236 239 2113 2116 O
castrate 240 248 2117 2125 B-cancer
prostate 249 257 2126 2134 I-cancer
cancer 258 264 2135 2141 I-cancer
or 265 267 2142 2144 O
nonmetastatic 268 281 2145 2158 B-cancer
( 282 283 2159 2160 I-cancer
M0 283 285 2160 2162 I-cancer
) 285 286 2162 2163 I-cancer
CRPC 287 291 2164 2168 I-cancer

Eastern 0 7 2169 2176 B-clinical_variable
Cooperative 8 19 2177 2188 I-clinical_variable
Oncology 20 28 2189 2197 I-clinical_variable
Group 29 34 2198 2203 I-clinical_variable
( 35 36 2204 2205 I-clinical_variable
ECOG 36 40 2205 2209 I-clinical_variable
) 40 41 2209 2210 I-clinical_variable
performance 42 53 2211 2222 I-clinical_variable
status 54 60 2223 2229 I-clinical_variable
of 61 63 2230 2232 O
0 64 65 2233 2234 B-lower_bound
to 66 68 2235 2237 O
2 69 70 2238 2239 B-upper_bound

Estimated 0 9 2240 2249 O
life 10 14 2250 2254 B-clinical_variable
expectancy 15 25 2255 2265 I-clinical_variable
of 26 28 2266 2268 O
â‰¥ 29 30 2269 2270 O
6 31 32 2271 2272 B-lower_bound
months 33 39 2273 2279 I-lower_bound
as 40 42 2280 2282 O
assessed 43 51 2283 2291 O
by 52 54 2292 2294 O
the 55 58 2295 2298 O
investigator 59 71 2299 2311 O

Fertile 0 7 2312 2319 O
male 8 12 2320 2324 B-gender
subjects 13 21 2325 2333 I-gender
who 22 25 2334 2337 O
are 26 29 2338 2341 O
unwilling 30 39 2342 2351 B-contraception_consent
or 40 42 2352 2354 I-contraception_consent
unable 43 49 2355 2361 I-contraception_consent
to 50 52 2362 2364 I-contraception_consent
use 53 56 2365 2368 I-contraception_consent
a 57 58 2369 2370 I-contraception_consent
highly 59 65 2371 2377 I-contraception_consent
effective 66 75 2378 2387 I-contraception_consent
method 76 82 2388 2394 I-contraception_consent
of 83 85 2395 2397 I-contraception_consent
contraception 86 99 2398 2411 I-contraception_consent
as 100 102 2412 2414 O
outlined 103 111 2415 2423 O
in 112 114 2424 2426 O
this 115 119 2427 2431 O
protocol 120 128 2432 2440 O
for 129 132 2441 2444 O
the 133 136 2445 2448 O
duration 137 145 2449 2457 O
of 146 148 2458 2460 O
the 149 152 2461 2464 O
study 153 158 2465 2470 O
and 159 162 2471 2474 O
for 163 166 2475 2478 O
at 167 169 2479 2481 O
least 170 175 2482 2487 O
4 176 177 2488 2489 B-lower_bound
months 178 184 2490 2496 I-lower_bound
after 185 190 2497 2502 O
the 191 194 2503 2506 O
last 195 199 2507 2511 O
dose 200 204 2512 2516 O
of 205 207 2517 2519 O
investigational 208 223 2520 2535 O
product 224 231 2536 2543 O

Gastrointestinal 0 16 2544 2560 B-chronic_disease
disorder 17 25 2561 2569 I-chronic_disease
affecting 26 35 2570 2579 O
absorption 36 46 2580 2590 O

History 0 7 2591 2598 O
of 8 10 2599 2601 O
another 11 18 2602 2609 O
cancer 19 25 2610 2616 B-cancer
within 26 32 2617 2623 O
3 33 34 2624 2625 B-upper_bound
years 35 40 2626 2631 I-upper_bound
before 41 47 2632 2638 O
enrollment 48 58 2639 2649 O
with 59 63 2650 2654 O
the 64 67 2655 2658 O
exception 68 77 2659 2668 O
of 78 80 2669 2671 O
nonmelanoma 81 92 2672 2683 B-cancer
skin 93 97 2684 2688 I-cancer
cancers 98 105 2689 2696 I-cancer
, 105 106 2696 2697 O
or 107 109 2698 2700 O
American 110 118 2701 2709 O
Joint 119 124 2710 2715 O
Committee 125 134 2716 2725 O
on 135 137 2726 2728 O
Cancer 138 144 2729 2735 O
stage 145 150 2736 2741 O
0 151 152 2742 2743 O
or 153 155 2744 2746 O
stage 156 161 2747 2752 O
1 162 163 2753 2754 O
cancer 164 170 2755 2761 O
that 171 175 2762 2766 O
has 176 179 2767 2770 O
a 180 181 2771 2772 O
remote 182 188 2773 2779 O
probability 189 200 2780 2791 O
of 201 203 2792 2794 O
recurrence 204 214 2795 2805 O
in 215 217 2806 2808 O
the 218 221 2809 2812 O
opinion 222 229 2813 2820 O
of 230 232 2821 2823 O
the 233 236 2824 2827 O
investigator 237 249 2828 2840 O
and 250 253 2841 2844 O
the 254 257 2845 2848 O
sponsor 258 265 2849 2856 O

Known 0 5 2857 2862 O
or 6 8 2863 2865 O
suspected 9 18 2866 2875 O
brain 19 24 2876 2881 B-cancer
metastasis 25 35 2882 2892 I-cancer
or 36 38 2893 2895 O
active 39 45 2896 2902 O
leptomeningeal 46 60 2903 2917 B-cancer
disease 61 68 2918 2925 I-cancer

Major 0 5 2926 2931 B-treatment
surgery 6 13 2932 2939 I-treatment
within 14 20 2940 2946 O
2 21 22 2947 2948 B-upper_bound
weeks 23 28 2949 2954 I-upper_bound
before 29 35 2955 2961 O
day 36 39 2962 2965 O
1 40 41 2966 2967 O

Must 0 4 2968 2972 O
use 5 8 2973 2976 O
a 9 10 2977 2978 O
condom 11 17 2979 2985 O
when 18 22 2986 2990 O
having 23 29 2991 2997 O
sex 30 33 2998 3001 O
from 34 38 3002 3006 O
the 39 42 3007 3010 O
time 43 47 3011 3015 O
of 48 50 3016 3018 O
the 51 54 3019 3022 O
first 55 60 3023 3028 O
dose 61 65 3029 3033 O
of 66 68 3034 3036 O
study 69 74 3037 3042 O
drug 75 79 3043 3047 O
through 80 87 3048 3055 O
4 88 89 3056 3057 B-upper_bound
months 90 96 3058 3064 I-upper_bound
after 97 102 3065 3070 O
last 103 107 3071 3075 O
dose 108 112 3076 3080 O
of 113 115 3081 3083 O
study 116 121 3084 3089 O
drug 122 126 3090 3094 O

Patients 0 8 3095 3103 O
must 9 13 3104 3108 O
have 14 18 3109 3113 O
measurable 19 29 3114 3124 O
soft 30 34 3125 3129 O
tissue 35 41 3130 3136 B-chronic_disease
disease 42 49 3137 3144 I-chronic_disease
per 50 53 3145 3148 O
RECIST 54 60 3149 3155 O
1.1 61 64 3156 3159 O

Patients 0 8 3160 3168 O
who 9 12 3169 3172 O
discontinued 13 25 3173 3185 O
prior 26 31 3186 3191 B-treatment
platinum 32 40 3192 3200 I-treatment
based 41 46 3201 3206 I-treatment
chemotherapy 47 59 3207 3219 I-treatment
< 60 61 3220 3221 O
= 61 62 3221 3222 O
6 62 63 3222 3223 B-upper_bound
months 64 70 3224 3230 I-upper_bound
prior 71 76 3231 3236 I-upper_bound
to 77 79 3237 3239 O
screening 80 89 3240 3249 O
or 90 92 3250 3252 O
whose 93 98 3253 3258 O
disease 99 106 3259 3266 O
previously 107 117 3267 3277 O
progressed 118 128 3278 3288 O
on 129 131 3289 3291 O
platinum 132 140 3292 3300 B-treatment
based 141 146 3301 3306 I-treatment
therapy 147 154 3307 3314 I-treatment
at 155 157 3315 3317 O
any 158 161 3318 3321 O
time 162 166 3322 3326 O
in 167 169 3327 3329 O
the 170 173 3330 3333 O
past 174 178 3334 3338 O

Prior 0 5 3339 3344 O
diagnosis 6 15 3345 3354 O
of 16 18 3355 3357 O
myelodysplastic 19 34 3358 3373 B-cancer
syndrome 35 43 3374 3382 I-cancer
or 44 46 3383 3385 O
acute 47 52 3386 3391 B-cancer
myeloid 53 60 3392 3399 I-cancer
leukemia 61 69 3400 3408 I-cancer

Significant 0 11 3409 3420 O
renal 12 17 3421 3426 B-chronic_disease
, 17 18 3426 3427 O
hepatic 19 26 3428 3435 B-chronic_disease
, 26 27 3435 3436 O
or 28 30 3437 3439 O
bone 31 35 3440 3444 B-chronic_disease
marrow 36 42 3445 3451 I-chronic_disease
organ 43 48 3452 3457 I-chronic_disease
dysfunction 49 60 3458 3469 I-chronic_disease

Soft 0 4 3470 3474 B-chronic_disease
tissue 5 11 3475 3481 I-chronic_disease
disease 12 19 3482 3489 I-chronic_disease
progression 20 31 3490 3501 O
as 32 34 3502 3504 O
defined 35 42 3505 3512 O
by 43 45 3513 3515 O
RECIST 46 52 3516 3522 O
1.1 53 56 3523 3526 O

Symptomatic 0 11 3527 3538 B-chronic_disease
or 12 14 3539 3541 I-chronic_disease
impending 15 24 3542 3551 I-chronic_disease
spinal 25 31 3552 3558 I-chronic_disease
cord 32 36 3559 3563 I-chronic_disease
compression 37 48 3564 3575 I-chronic_disease
or 49 51 3576 3578 O
cauda 52 57 3579 3584 B-chronic_disease
equina 58 64 3585 3591 I-chronic_disease
syndrome 65 73 3592 3600 I-chronic_disease

Treatment 0 9 3601 3610 B-treatment
with 10 14 3611 3615 I-treatment
any 15 18 3616 3619 I-treatment
concurrent 19 29 3620 3630 I-treatment
cytotoxic 30 39 3631 3640 I-treatment
chemotherapy 40 52 3641 3653 I-treatment
or 53 55 3654 3656 I-treatment
investigational 56 71 3657 3672 I-treatment
drug(s 72 78 3673 3679 I-treatment
) 78 79 3679 3680 I-treatment
within 80 86 3681 3687 O
4 87 88 3688 3689 B-upper_bound
weeks 89 94 3690 3695 I-upper_bound
or 95 97 3696 3698 O
5 98 99 3699 3700 O
half 100 104 3701 3705 O
lives 105 110 3706 3711 O
of 111 113 3712 3714 O
the 114 117 3715 3718 O
drug 118 122 3719 3723 O
( 123 124 3724 3725 O
whichever 124 133 3725 3734 O
is 134 136 3735 3737 O
longer 137 143 3738 3744 O
) 143 144 3744 3745 O
before 145 151 3746 3752 O
Day 152 155 3753 3756 O
1 156 157 3757 3758 O
and/or 158 164 3759 3765 O
during 165 171 3766 3772 O
study 172 177 3773 3778 O
participation 178 191 3779 3792 O

